Subsequent phase III trials demonstrated that the dose chosen from the integrated evaluation of multiple endpoints across high- and low-immunogenic tumor types resulted in survival benefits to patients irrespective of PD-L1 expression levels [4, 13, 20, 21]. The gene discussed is CD274; the disease is neoplasm.